高迁移率族蛋白B1与可溶性晚期糖基化终产物受体血清水平与干燥综合征腺外受累及疾病活动相关
ELISA法检测的HMGB-1在两组间无差异(P=0.783),但半定量Western blotting检测的HMGB-1在SS患者中升高(P=0.012),且腺外受累者更高(P=0.003),与ESSDAI相关(r=0.544,P<0.0001)。sRAGE在SS患者中也升高(P=0.003),并与ESSDAI相关(r=0.545,P=0.002)。
要点
- Western blotting检测的HMGB-1在SS患者中升高且与腺外受累及ESSDAI相关
- ELISA检测的HMGB-1在SS与健康对照间无差异
- sRAGE在SS患者中升高并与ESSDAI相关
核心结论
- SS患者血清总HMGB-1(Western blotting检测)和sRAGE水平较健康对照升高,且与ESSDAI评估的疾病活动度相关。
- 伴有腺外受累的SS患者血清HMGB-1水平更高。
研究设计与样本
- 采用ELISA检测血清HMGB-1和sRAGE水平,并用Western blotting半定量检测HMGB-1。
- 疾病活动度采用欧洲抗风湿病联盟SS疾病活动指数(ESSDAI)评估。
主要发现
- ELISA检测的HMGB-1血清水平在健康对照与SS患者间无差异(P=0.783)。
- Western blotting半定量检测的HMGB-1在SS患者中较健康对照升高(P=0.012)。
- Western blotting检测的HMGB-1在有腺外表现的患者中更高(P=0.003),并与ESSDAI疾病活动度相关(r=0.544,P<0.0001)。
- sRAGE在SS患者血清中较健康对照升高(P=0.003),并与ESSDAI相关(r=0.545,P=0.002)。
关键数值与推荐
- HMGB-1(ELISA)组间比较P=0.783;HMGB-1(Western blotting)组间比较P=0.012。
- HMGB-1(Western blotting)与腺外表现比较P=0.003;与ESSDAI相关r=0.544,P<0.0001。
- sRAGE组间比较P=0.003;与ESSDAI相关r=0.545,P=0.002。
临床怎么用
- Western blotting检测的HMGB-1和sRAGE或可作为评估SS疾病活动度及腺外受累的血清标志物。
- ELISA检测的HMGB-1未能区分SS与健康对照,临床解读需注意检测方法差异。
局限性
- 横断面设计无法推断因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess serum levels of high mobility group box chromosomal protein 1 (HMGB-1) and the soluble receptor for advanced glycation end products (sRAGE) in patients with Sjögren's syndrome (SS) and explore correlations with disease activity. METHODS: Thirty-nine patients with SS and 21 healthy controls were included in this cross-sectional study. Clinical and laboratory values were obtained from all patients. Disease activity was assessed using the European League Against Rheumatism SS Disease Activity Index (ESSDAI). Serum samples were collected and HMGB-1 and sRAGE levels were measured using enzyme-linked immunosorbent assay (ELISA), and HMGB-1 concentrations were semiquantified by Western blotting. RESULTS: In ELISA, HMGB-1 serum levels did not differ between healthy controls and patients with SS (P = 0.783). When measured by semiquantitative Western blotting, HMGB-1 levels were increased in patients with SS compared to healthy controls (P = 0.012). HMGB-1 serum levels detected by Western blotting were higher in patients with extraglandular manifestations (P = 0.003) and were correlated with ESSDAI disease activity (r = 0.544, P < 0.0001). Furthermore, sRAGE was elevated in the sera of patients with SS (P = 0.003) compared to healthy controls and was also correlated with the ESSDAI (r = 0.545, P = 0.002). CONCLUSION: Serum levels of total HMGB-1 and sRAGE were elevated in patients with SS compared to healthy controls and correlated with disease activity as measured by the ESSDAI. Patients with extraglandular involvement had high serum levels of HMGB-1.
引用
- Kanne AM, Jülich M, Mahmutovic A, et al. Association of High Mobility Group Box Chromosomal Protein 1 and Receptor for Advanced Glycation End Products Serum Concentrations With Extraglandular Involvement and Disease Activity in Sjögren's Syndrome. Arthritis Care Res (Hoboken). 2018. PMID: 28941024. doi:10.1002/acr.23420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。